logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Nuvig Therapeutics raised $161 million in a Series B funding round co-led by Sanofi Ventures and Blue Owl Healthcare Opportunities to support the clinical development of its novel immunomodulatory therapeutics.

Dec 05, 2024•about 1 year ago

Amount Raised

$161 Million

Round Type

series b

Menlo ParkresearchTherapeuticsBiotechnologyHealth Care

Investors

Mission Bio CapitalDigitalis VenturesBristol Myers SquibbPlatanusNovo Holdings A/SAbrdn Inc.Alexandria Venture InvestmentsLotte HoldingsGlobal Bio Access FundLeaps By BayerB CapitalNorwest Venture PartnersBlue Owl Healthcare OpportunitiesSanofi Ventures

Description

Nuvig Therapeutics announced the closing of a $161 million Series B financing to advance its novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases. The financing will support clinical proof-of-concept studies for lead candidate NVG-2089 and the company's preclinical pipeline.

Company Information

Company

Nuvig Therapeutics

Location

4200 Bohannon Dr

Menlo Park, California, United States

About

Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.

Related People

4 contacts

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech